Applied DNA Sciences Second Quarter 2025 Earnings: Misses Expectations
Net income: US$20.6m (up from US$4.63m loss in 2Q 2024).
EPS: US$11.63 (up from US$265 loss in 2Q 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates.
Looking ahead, revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 18% from a week ago.
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Applied DNA Sciences (4 shouldn't be ignored) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Google is working on a new Gemini logo with familiar colors
Just when we thought Gemini couldn't be Google-fied anymore, the Mountain View, California-based company succeeded in surprising us. Soon after the tech giant began rolling out Song Search on the Android Gemini app, paired with support for Scheduled Actions, it now seems to be giving the Gemini app and its logo a more Google-esque look. The app's familiar blue and purple tone, which can be observed across instances of the Gemini branding, is in the midst of being replaced with a more colorful hue — one that looks similar to Google Assistants signature multicolored branding. Hints about the redesign were spotted in the latest Google app beta build (version beta) by the folks over at Android Authority, surfacing Google's well-known color palette across the app's UI. Old, new, old, new The change was observed in the app's splash screen, which highlights an animated red, yellow, green, and blue Gemini logo for a brief second when you open a new instance of the app. Similarly, the logo on the onboarding screen appears in the same Google-themed colors, as seen in the screenshots above. Eagle-eyed users would have also spotted the lack of blue and purple on the "Get to know Gemini, your AI assistant" text at the top. The change also makes its way to the Gemini logo that appears above the AI tool's responses. These aren't huge changes by any means, and won't change the way users utilize Gemini. However, the refresh does make the experience feel a little more aligned and consistent with Google's overall brand identity. For what it's worth, these changes were manually enabled, and they won't surface for you in the beta build of the app just yet. The changes will likely make their way out widely with a future update, which might happen around the time when Google Assistant is fully phased out later this year. Google Gemini Google LLC PRODUCTIVITY Price: Free 4.5 Download
Yahoo
23 minutes ago
- Yahoo
Doctor Care Anywhere Group PLC's (ASX:DOC) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Doctor Care Anywhere Group PLC's () future prospects. Doctor Care Anywhere Group PLC, together with its subsidiaries, provides digital healthcare and development services in the United Kingdom and the Republic of Ireland. The AU$38m market-cap company announced a latest loss of UK£5.1m on 31 December 2024 for its most recent financial year result. As path to profitability is the topic on Doctor Care Anywhere Group's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Expectations from some of the Australian Healthcare Services analysts is that Doctor Care Anywhere Group is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of UK£100k in 2026. Therefore, the company is expected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 105%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. Given this is a high-level overview, we won't go into details of Doctor Care Anywhere Group's upcoming projects, but, bear in mind that generally healthcare tech companies, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. View our latest analysis for Doctor Care Anywhere Group One thing we would like to bring into light with Doctor Care Anywhere Group is it currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning. There are too many aspects of Doctor Care Anywhere Group to cover in one brief article, but the key fundamentals for the company can all be found in one place – Doctor Care Anywhere Group's company page on Simply Wall St. We've also put together a list of pertinent aspects you should look at: Valuation: What is Doctor Care Anywhere Group worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Doctor Care Anywhere Group is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Doctor Care Anywhere Group's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
The stock market has a secret weapon that's powering record highs
Morgan Stanley sees stock market recovery with potential for more all-time highs. Earnings revisions breadth has improved, driven by more positive analyst estimates. The S&P 500 expected to reach 6,500, aided by earnings growth and a weaker dollar. The stock market has made an impressive recovery from its April low, and Morgan Stanley sees one strong sign that the gains are set to continue. With trade concerns and geopolitical conflicts easing, the market made new highs again on Monday, adding to gains amid fresh progress on trade. Here's where major indexes stood at 11:50 a.m. ET on Monday: S&P 500: 6,190.75, up 0.23% Dow Jones Industrial Average: 44,027.87, up 0.37% (+160.76 points) Nasdaq Composite: 20,338.95, up 0.25% As headwinds from earlier this year, such as tariffs and fears of an AI spending slowdown, begin to ease, a key source of strength for the stock market has rebounded. Earnings revisions breadth, or the proportion of analysts who have raised their estimates minus the proportion who have lowered them, has improved significantly in the past few months. In April, Bloomberg Intelligence data found that estimates for earnings-per-share growth had fallen from 11.4% to 6.9% since the beginning of 2025. At the April bottom, earnings revision breadth stood at -25%. It's since improved to -5%, and its recovery has been swift. Earlier in June, earnings revisions breadth was at -10%. Going forward, Morgan Stanley anticipates a bullish rate of change on EPS revisions to be a key factor in further stock market gains, especially as earnings revisions breadth ticks closer to a positive number. "On that score, specifically, the message is crystal clear. The ERB bottomed on April 17th around MSFT's earnings report and has not looked back since," Morgan Stanley analysts led by chief investment officer Mike Wilson wrote. "As we have noted for the past couple of months, the recovery in this metric has been more about positive revisions rather than fewer negative ones and when that is the case, the forward equity market returns tend to be stronger," More upward revisions have typically led to 12% S&P 500 stock gains in the next 12 months, while fewer negative revisions have led to only 8% gains over the same time period, they added. Morgan Stanley expects the S&P 500 to end the year at 6,500, implying a gain of about 5% from current record levels. With analysts growing more bullish on corporate earnings, the outlook points to a potentially sustainable growth trajectory. The bank attributes the plunge in earnings estimates earlier this year largely to perceived weakness in the Magnificent Seven stocks. But now, earnings growth is on track to outperform overall economic growth, something that wasn't the case in the 2022 to 2024 bull market. The bank expects a weaker dollar and tax incentives from the Big Beautiful Bill to continue encouraging positive earnings outlooks, and also contribute to a broadening market. "As we head into the second half of the year, the equity market is likely to be driven by more bullish rate of change on EPS revisions, monetary policy expectations, and back-end rates/term premium," Mike Wilson, the bank's chief equity strategist, wrote. "This is a notably different environment than large parts of 2023-2024 when prospects of easier monetary and fiscal policy drove markets higher despite stagnating EPS revisions." Read the original article on Business Insider Sign in to access your portfolio
